Skip to main content
Top
Published in: Breast Cancer Research and Treatment 2/2019

01-06-2019 | Breast Cancer | Epidemiology

Health-related quality of life in long-term disease-free breast cancer survivors versus female population controls in Germany

Authors: Daniela Doege, Melissa Suk-Yin Thong, Lena Koch-Gallenkamp, Heike Bertram, Andrea Eberle, Bernd Holleczek, Ron Pritzkuleit, Mechthild Waldeyer-Sauerland, Annika Waldmann, Sylke Ruth Zeissig, Lina Jansen, Hermann Brenner, Volker Arndt

Published in: Breast Cancer Research and Treatment | Issue 2/2019

Login to get access

Abstract

Purpose

Little is known about breast cancer (BC) survivors’ health-related quality of life (HRQoL) > 5 or even > 10 years past diagnosis. It is of interest whether, in the long run, survivors’ HRQoL aligns with that of the general population. Study objectives were to (1) compare disease-free BC survivors’ HRQoL to that of non-cancer controls, and (2) compare long-term survivors (LTS, 5–9 years post-diagnosis), very long-term survivors (VLTS, ≥ 10 years post-diagnosis), and controls with respect to their HRQoL.

Methods

The samples of 2647 disease-free BC survivors (5–16 years post-diagnosis) and 1005 population controls were recruited in German multi-regional population-based studies. HRQoL was assessed by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire—Core 30 (EORTC QLQ-C30). Differences in HRQoL were assessed with multiple regression, controlling for age and education.

Results

Disease-free BC survivors < 80 years (at survey) reported overall global health status/quality of life comparable to controls, but statistically significant lower physical, role, emotional, social, and cognitive functioning. They also indicated more fatigue, insomnia, dyspnoea, and financial difficulties. However, differences were only of trivial or small clinical relevance. At age 80–89, no differences between BC survivors and controls were observed. Deficits in emotional and cognitive functioning and some symptoms (e.g. insomnia and fatigue) persist, as both LTS and VLTS reported more detriments than controls.

Conclusions

In view of the persistent, small but significant detriments in disease-free BC survivors’ cognitive and emotional functioning and higher symptom burden, possibilities to prevent detriments from becoming chronic should be explored.
Appendix
Available only for authorised users
Literature
1.
go back to reference Bericht zum Krebsgeschehen in Deutschland 2016 (2016) Zentrum für Krebsregisterdaten im Robert Koch-Institut (Hrsg). Berlin Bericht zum Krebsgeschehen in Deutschland 2016 (2016) Zentrum für Krebsregisterdaten im Robert Koch-Institut (Hrsg). Berlin
21.
go back to reference EORTC (2001) EORTC QLQ-C30 Scoring Manual. EORTC, Brussels EORTC (2001) EORTC QLQ-C30 Scoring Manual. EORTC, Brussels
26.
go back to reference Ganz PA, Desmond KA, Leedham B, Rowland JH, Meyerowitz BE, Belin TR (2002) Quality of life in long-term, disease-free survivors of breast cancer: a follow-up study. J Natl Cancer I 94(1):39–49CrossRef Ganz PA, Desmond KA, Leedham B, Rowland JH, Meyerowitz BE, Belin TR (2002) Quality of life in long-term, disease-free survivors of breast cancer: a follow-up study. J Natl Cancer I 94(1):39–49CrossRef
32.
go back to reference Duijts SFA, Faber MM, Oldenburg HSA, van Beurden M, Aaronson NK (2011) Effectiveness of behavioral techniques and physical exercise on psychosocial functioning and health-related quality of life in breast cancer patients and survivors—a meta-analysis. Psycho-Oncol 20(2):115–126. https://doi.org/10.1002/pon.1728 CrossRef Duijts SFA, Faber MM, Oldenburg HSA, van Beurden M, Aaronson NK (2011) Effectiveness of behavioral techniques and physical exercise on psychosocial functioning and health-related quality of life in breast cancer patients and survivors—a meta-analysis. Psycho-Oncol 20(2):115–126. https://​doi.​org/​10.​1002/​pon.​1728 CrossRef
Metadata
Title
Health-related quality of life in long-term disease-free breast cancer survivors versus female population controls in Germany
Authors
Daniela Doege
Melissa Suk-Yin Thong
Lena Koch-Gallenkamp
Heike Bertram
Andrea Eberle
Bernd Holleczek
Ron Pritzkuleit
Mechthild Waldeyer-Sauerland
Annika Waldmann
Sylke Ruth Zeissig
Lina Jansen
Hermann Brenner
Volker Arndt
Publication date
01-06-2019
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 2/2019
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-019-05188-x

Other articles of this Issue 2/2019

Breast Cancer Research and Treatment 2/2019 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine